공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

CD40 배간자(T세포 항원 GP39, TNF 관련 활성화 단백질, 종양괴사인자 슈퍼패밀리 멤버 5, CD154, CD40LG) : 파이프라인 리뷰

CD40 Ligand - Pipeline Review, H2 2019

리서치사 Global Markets Direct
발행일 2019년 12월 상품 코드 363562
페이지 정보 영문 74 Pages
가격
US $ 3,500 ₩ 4,009,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,000 ₩ 8,018,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,500 ₩ 12,027,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


CD40 배간자(T세포 항원 GP39, TNF 관련 활성화 단백질, 종양괴사인자 슈퍼패밀리 멤버 5, CD154, CD40LG) : 파이프라인 리뷰 CD40 Ligand - Pipeline Review, H2 2019
발행일 : 2019년 12월 페이지 정보 : 영문 74 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계 각국에서의 CD40 배위자(별칭 T세포 항원 GP40 또는 TNF 관련 활성화 단백질, 종양괴사인자 슈퍼패밀리 멤버 5, CD154, CD40LG) 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발 및 출시 동향, 임상시험 단계별 제품 일람, 주요 기업 프로파일, 주요 약제 개요, 최신 업계 동향 등의 정보를 전해드립니다.

목차

  • 서론
    • 분석 범위
  • CD40 리간드(T세포 항원 GP40, TNF 관련 활성화 단백질, 종양괴사인자 슈퍼패밀리 멤버 5, CD154, CD40LG) 개요
  • 치료제 개발 상황
    • 임상시험 단계별
    • 치료 영역별
    • 증상별
  • 파이프라인 제품 개요
    • 후기 단계 제품
    • 초기 단계 제품
  • 각 기업에서 개발중인 치료제
  • 치료제 평가
    • 단일요법(Monotherapy)/결합제품(Combination Products)별
    • 작용기전별
    • 투여 방법별
    • 분자 종류별
  • 치료제 개발에 참여하고 있는 기업
    • Biogen, Inc.
    • Bristol-Myers Squibb Company
    • eTheRNA Immunotherapies NV
    • ImmuNext, Inc.
    • Juno Therapeutics Inc.
    • MedImmune, LLC
    • Targovax AS
    • XL-protein GmbH
  • 치료제 개요
    • Antibodies to Antagonize CD40L for Autoimmune Diseases and GVHD
      • 제품 개요
      • 작용기전
      • 연구개발(R&D) 진전 상황
    • Antibody to Target CD40 Ligand for Immunology
    • BIIB-063
    • BMS-986004
    • Cellular Immunotherapy to Activate CD40L and to Target CD19 for B-Cell Malignancies
    • FFP-102
    • hepatitis B vaccine
    • ISF-35
    • LOAd-700
    • MEDI-4920
    • MegaCD40L
    • Oligonucleotide to Activate CD40L, CD70 and TLR-4 for Oncology and Infectious Diseases
    • ONCOS-402
    • TDI-28
    • TDI-846
    • UltraCD40L
    • Vaccine to Target CD40L and GM-CSF for Oncology
    • XL-050 - Drug Profile
  • 휴지 상태인 프로젝트
  • 주목해야 할 최신 동향과 프레스 릴리스(총 10건)
  • 부록

도표

LSH 16.08.03

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Anelixis Therapeutics LLC, H2 2019
  • Pipeline by Bristol-Myers Squibb Co, H2 2019
  • Pipeline by eTheRNA Immunotherapies NV, H2 2019
  • Pipeline by Memgen LLC, H2 2019
  • Pipeline by NapaJen Pharma Inc, H2 2019
  • Pipeline by Sanofi, H2 2019
  • Pipeline by Shattuck Labs Inc, H2 2019
  • Pipeline by TILT Biotherapeutics Ltd, H2 2019
  • Pipeline by Tonix Pharmaceuticals Holding Corp, H2 2019
  • Pipeline by UCB SA, H2 2019
  • Pipeline by Viela Bio Inc, H2 2019
  • Pipeline by XL-protein GmbH, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019

Summary

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - CD40 ligand or CD40L is a protein that is primarily expressed on activated T cells and is a member of the TNF superfamily. The CD40-CD40 ligand interaction is crucial to the development of T dependent immune responses. The ligand is expressed on a range of cell types including B cells, granulocytes, macrophages and platelets. T cells expressing CD40L provide signals to B cells that induce proliferation, immunoglobulin class switching, antibody secretion, and rescue from apoptosis at different times during the life of a B cell and also have a role in the development of germinal centres and the survival of memory B cells.

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) pipeline Target constitutes close to 19 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 3, 5 and 7 respectively. Similarly, the universities portfolio in Phase II and Preclinical stages comprises 2 and 2 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Central Nervous System and Genetic Disorders which include indications Autoimmune Disorders, Graft Versus Host Disease (GVHD), Amyotrophic Lateral Sclerosis, Breast Cancer, Multiple Sclerosis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Auto Inflammatory Disease, Bladder Cancer, Colon Cancer, Hepatocellular Carcinoma, Inflammation, Kidney Transplant Rejection, Lung Adenocarcinoma, Melanoma, Metastatic Melanoma, Non-Small Cell Lung Cancer, Pancreatic Islet Transplant Rejection, Sicca Syndrome (Sjogren), Solid Tumor and Transplant Rejection.

The latest report CD40 Ligand - Pipeline Review, H2 2019, outlays comprehensive information on the CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)
  • The report reviews CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics and enlists all their major and minor projects
  • The report assesses CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Overview
  • CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Companies Involved in Therapeutics Development
  • Anelixis Therapeutics LLC
  • Bristol-Myers Squibb Co
  • eTheRNA Immunotherapies NV
  • Memgen LLC
  • NapaJen Pharma Inc
  • Sanofi
  • Shattuck Labs Inc
  • TILT Biotherapeutics Ltd
  • Tonix Pharmaceuticals Holding Corp
  • UCB SA
  • Viela Bio Inc
  • XL-protein GmbH
  • CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Drug Profiles
  • AT-1501 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • dapirolizumab pegol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ECI-006 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Fusion Proteins for Inflammation - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Activate CD40LG for Genetic Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Target CD40 Ligand for Malignant Melanoma and Bladder Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ISF-35 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • letolizumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NJA-730 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SAR-441344 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SL-115154 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SL-172154 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TDI-28 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TILT-234 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TNX-1500 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaccine to Target Cancer Testis Antigen, CD80 and CD40L for Breast Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaccine to Target CD40L and GM-CSF for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VIB-4920 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • XL-050 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Dormant Products
  • CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Discontinued Products
  • CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Product Development Milestones
  • Featured News & Press Releases
  • Dec 11, 2019: Viela Bio announces initiation of phase 2b trial of VIB4920 in Sjogren's Syndrome
  • Nov 08, 2019: UCB Presents new data on investigational molecule Dapirolizumab Pegol at the 2019 American College of Rheumatology and the Association of Rheumatology Professionals (ACR/ARP) Annual Meeting
  • Aug 21, 2019: Tonix Pharmaceuticals and Massachusetts General Hospital enter into research collaboration to develop Tonixs third generation anti-CD154 monoclonal antibody, TNX-1500, for the treatment and prevention of organ transplant rejection
  • Jun 01, 2019: Safety and immune stimulation data from an intranodal delivery of TriMix mRNA, in the adjuvant melanoma study E011-MEL
  • Mar 04, 2019: eTheRNA immunotherapies completes patient enrolment for Phase Ib-study in adjuvant melanoma
  • Nov 28, 2018: Augie's Quest reports first subject successfully enrolled in AT-1501 phase 1 study, a first-of-its-kind, promising treatment for ALS
  • Nov 15, 2018: NapaJen Pharma announces first patient dosed in phase 1 first-in-human clinical trial of novel RNA interference (RNAi) therapeutic
  • Oct 23, 2018: UCB and Biogen announce topline results from a phase 2b study of Dapirolizumab Pegol in Systemic Lupus Erythematosus
  • Oct 19, 2018: Viela Bio Announces Late-Breaking Abstract Acceptance for VIB4920 at the 2018 ACR/ARHP Annual Meeting
  • Oct 08, 2018: eTheRNA Opens State-of-the-art Manufacturing Facility in Belgium to Support the Development of its TriMix-based mRNA Cancer Immunotherapies
  • May 24, 2018: eTheRNA Enrols First Patient in High Dose Cohort of Phase 1b study of TriMix mRNA-based Cancer Specific Immunotherapy (ECI-006) in Melanoma
  • Mar 19, 2018: eTheRNA completes enrolment of low dose cohort for Phase 1b study of TriMix mRNA-based cancer specific immunotherapy (ECI-006) in melanoma
  • Jun 30, 2017: etherna Advances in-vivo MRNA Cancer Immunotherapy Into First Oncology Clinical Studies
  • Jun 08, 2016: UCB presents Phase 1 results for dapirolizumab pegol at the Annual European Congress of Rheumatology (EULAR 2016)
  • Nov 17, 2015: Memgen Announces Preclinical Results for ISF35 in Combination with Checkpoint Inhibitors in a Model of Metastatic Melanoma
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q